Activity – Page 15

Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma

1 year ago talkbio0Tagged Acquisition (action), Capacity, Eli Lilly, expansion, Facility (object), Injectables, Nexus Pharma, pharmaceutical manufacturing, production, strategic

Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.

Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma

1 year ago talkbio0Tagged Acquisition (action), Biopharma, development aspects, Drug Development, Drug Industry, innovative assets, Market, Partnership, Portfolio diversification, Risk Management, strategic decision-making, trends qualifier

Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification

Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction

1 year ago talkbio0Tagged Drug Development, high-impact projects, Optimization, portfolio, Roche (company), strategic decision

Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition

1 year ago talkbio0Tagged Acquisition (action), Dosage Forms, Drug Development, Escient, Fibrosis, Incyte, Inflammatory disorder, mast cell inhibitors

Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million

Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Drug Development, Escient, expansion, G-Protein-Coupled Receptors, Immune system, Incyte, Neuroscience discipline, portfolio, targets

Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.

Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Clinical Trials, Drug Development, Drug Industry, Investments, Phase III, Principia, Rilzabrutinib, sanofi, strategic, Success

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

1 year ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development

1 year ago talkbio0Tagged approvals, Biological Assay, Biological Markers, Biomarker Strategy, Clinical Development, Clinical Trial Design, Cross-Functional Collaboration, development aspects, Discover, Drug Molecule Development, End Point, Leadership, PK/ PD/, Preclinical Development, regulatory, Target, Team Building, Translational Research, Biomedical, Translational Science Leadership

Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

1 year ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction